Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07798947 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC

Name: A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC — clinical trial record (NCT07798947)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorShanghai Hengrui Pharmaceutical Co., Ltd.

Started2026-09

View on ClinicalTrials.gov ↗

This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.

Trial Details

NCT Number	NCT07798947
Lead Sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions	Limited-stage Small-cell Lung Cancer
Enrollment	120 participants
Start Date	2026-09
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-02